GB9105489D0
(en)
*
|
1991-03-15 |
1991-05-01 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
GB9126677D0
(en)
*
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
KR100447303B1
(ko)
*
|
1994-01-11 |
2005-08-23 |
아노메드 인코포레이티드 |
고리형폴리아민
|
GB9400411D0
(en)
*
|
1994-01-11 |
1994-03-09 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
US5663161A
(en)
*
|
1995-02-17 |
1997-09-02 |
The Research Foundation Of State University Of New York |
Anti-viral triaza compounds
|
US5612478A
(en)
*
|
1995-03-30 |
1997-03-18 |
Johnson Matthey Plc |
Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
|
US5606053A
(en)
*
|
1995-05-02 |
1997-02-25 |
Johnson Matthey Plc |
Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
|
GB9511357D0
(en)
*
|
1995-06-06 |
1995-08-02 |
Johnson Matthey Plc |
Improved antiviral compounds
|
US6506770B1
(en)
|
1996-06-06 |
2003-01-14 |
Anormed, Inc. |
Antiviral compounds
|
CA2224003C
(en)
*
|
1995-06-07 |
2010-04-13 |
Progenics Pharmaceuticals, Inc. |
Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
|
US5874573A
(en)
*
|
1995-06-26 |
1999-02-23 |
Concat, Inc. |
Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy
|
US5608061A
(en)
*
|
1995-08-02 |
1997-03-04 |
Johnson Matthey Plc |
Process for preparing 1,4,8,11-tetraazacyclotetradecane
|
US7118859B2
(en)
|
1996-01-17 |
2006-10-10 |
Progenics Pharmaceuticals, Inc. |
Methods for inhibiting HIV-1 infection
|
US6344545B1
(en)
|
1996-06-14 |
2002-02-05 |
Progenics Pharmaceuticals, Inc. |
Method for preventing HIV-1 infection of CD4+ cells
|
US7858298B1
(en)
|
1996-04-01 |
2010-12-28 |
Progenics Pharmaceuticals Inc. |
Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
|
US20040086528A1
(en)
*
|
1996-06-14 |
2004-05-06 |
Progenics Pharmaceuticals, Inc. |
Uses of a chemokine receptor for inhibiting HIV-1 infection
|
AU5241099A
(en)
*
|
1998-07-31 |
2000-02-21 |
Trustees Of Columbia University In The City Of New York, The |
Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
|
US20080015348A1
(en)
*
|
1998-12-16 |
2008-01-17 |
Progenics Pharmaceuticals, Inc. |
Nucleic acids encoding polypeptides of anti-CCR5 antibodies
|
US20040228869A1
(en)
*
|
1998-12-16 |
2004-11-18 |
Progenics Pharmaceuticals, Inc. |
Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
|
US6365583B1
(en)
*
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
US6750348B1
(en)
|
1999-03-24 |
2004-06-15 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds
|
MXPA01009674A
(es)
*
|
1999-03-24 |
2003-07-21 |
Anormed Inc |
Compuestos heterociclicos que se unen a receptores de quimiocina.
|
AU4678300A
(en)
*
|
1999-04-30 |
2000-11-17 |
Slil Biomedical Corporation |
Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
|
US6482943B1
(en)
|
1999-04-30 |
2002-11-19 |
Slil Biomedical Corporation |
Quinones as disease therapies
|
NZ515140A
(en)
*
|
1999-04-30 |
2003-07-25 |
Slil Biomedical Corp |
Conformationally restricted polyamine analogs as disease therapies for cancer, epilepsy, alzheimers, infections, grafts and others
|
US6649587B1
(en)
|
1999-04-30 |
2003-11-18 |
Slil Biomedical Corporation |
Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
|
US8271316B2
(en)
*
|
1999-12-17 |
2012-09-18 |
Buzzmetrics Ltd |
Consumer to business data capturing system
|
ATE428706T1
(de)
*
|
1999-12-17 |
2009-05-15 |
Genzyme Corp |
Chemokinrezeptor-bindende heterocyclische verbindungen
|
US20030072715A1
(en)
*
|
2000-08-02 |
2003-04-17 |
Benjamin Frydman |
Cyclic polyamine compounds for cancer therapy
|
SG126007A1
(en)
*
|
2000-09-15 |
2006-10-30 |
Anormed Inc |
Chemokine receptor binding hetrocyclic compounds
|
US7138119B2
(en)
*
|
2000-09-15 |
2006-11-21 |
Progenics Pharmaceuticals, Inc. |
Compositions and methods for inhibition of HIV-1 infection
|
ATE487710T1
(de)
|
2000-09-15 |
2010-11-15 |
Anormed Inc |
Chemokin rezeptor bindende heterozyklische verbindungen
|
IL154400A0
(en)
|
2000-09-29 |
2003-09-17 |
Anormed Inc |
Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
|
WO2002091989A2
(en)
*
|
2000-11-08 |
2002-11-21 |
Slil Biomedical Corporation |
Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
|
US7060273B2
(en)
*
|
2001-04-06 |
2006-06-13 |
Progenics Pharmaceuticals, Inc. |
Methods for inhibiting HIV-1 infection
|
ES2380009T3
(es)
|
2001-07-31 |
2012-05-07 |
Genzyme Global S.A.R.L. |
Métodos para movilizar las células madre/progenitoras
|
US7169750B2
(en)
*
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
JP2005511734A
(ja)
*
|
2001-12-07 |
2005-04-28 |
スリル バイオメディカル コーポレイション |
癌治療用のシクロアルキル置換ポリアミンおよびそれらの合成方法
|
CA2467718C
(en)
|
2001-12-21 |
2011-04-26 |
Anormed Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7354932B2
(en)
*
|
2001-12-21 |
2008-04-08 |
Anormed, Inc. |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7122185B2
(en)
*
|
2002-02-22 |
2006-10-17 |
Progenics Pharmaceuticals, Inc. |
Anti-CCR5 antibody
|
CA2520259A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Anormed Inc. |
Cxcr4 chemokine receptor binding compounds
|
US7501518B2
(en)
*
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
EP2374804A1
(en)
*
|
2003-04-22 |
2011-10-12 |
Genzyme Corporation |
Chemokine receptor binding heterocyclic compounds with enhanced efficacy
|
US7491735B2
(en)
*
|
2003-12-11 |
2009-02-17 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
US7498346B2
(en)
*
|
2003-12-11 |
2009-03-03 |
Genzyme Corporation |
Chemokine receptor binding compounds
|
EP1796716A4
(en)
*
|
2004-08-13 |
2010-09-08 |
Anormed Inc |
COMBINATIONS OF CHEMOKINES FOR MOBILIZING PROGENITOR / STEM CELLS
|
JP2008543858A
(ja)
*
|
2005-06-15 |
2008-12-04 |
ジェンザイム・コーポレーション |
ケモカインレセプター結合化合物
|
CN101309690A
(zh)
*
|
2005-08-16 |
2008-11-19 |
阿诺麦德股份有限公司 |
趋化因子受体结合化合物
|
US20070043012A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Bridger Gary J |
Methods to enhance chemotherapy
|
MX2008010895A
(es)
*
|
2006-02-24 |
2008-09-03 |
Genzyme Corp |
Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.
|
BRPI0714799A2
(pt)
*
|
2006-08-02 |
2013-05-21 |
Genzyme Corp |
terapia de combinaÇço
|
WO2008019371A1
(en)
*
|
2006-08-07 |
2008-02-14 |
Genzyme Corporation |
Combination therapy
|
WO2012158707A1
(en)
|
2011-05-16 |
2012-11-22 |
Genzyme Corporation |
Use of cxcr4 antagonists
|
AU2016269839B2
(en)
|
2015-06-03 |
2021-07-08 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
JP6958820B2
(ja)
|
2015-12-14 |
2021-11-02 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置する方法
|
CA3008272A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
US11433136B2
(en)
|
2015-12-18 |
2022-09-06 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
CN108883091A
(zh)
|
2015-12-22 |
2018-11-23 |
X4 制药有限公司 |
用于治疗免疫缺陷病的方法
|
CN109153722A
(zh)
|
2016-04-08 |
2019-01-04 |
X4 制药有限公司 |
用于治疗癌症的方法
|
WO2017223229A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
CN109641838A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
CA3079405A1
(en)
|
2017-10-31 |
2019-05-09 |
Magenta Therapeutics Inc. |
Compositions and methods for the expansion of hematopoietic stem and progenitor cells
|
JP2021503008A
(ja)
|
2017-10-31 |
2021-02-04 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
造血幹細胞および前駆細胞移植療法のための組成物および方法
|
US11260079B2
(en)
|
2017-12-06 |
2022-03-01 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
EP3720494A2
(en)
|
2017-12-06 |
2020-10-14 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
WO2019136159A1
(en)
|
2018-01-03 |
2019-07-11 |
Magenta Therapeutics Inc. |
Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
US20220401481A1
(en)
|
2019-11-01 |
2022-12-22 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
JP2023523334A
(ja)
|
2020-04-27 |
2023-06-02 |
マジェンタ セラピューティクス インコーポレイテッド |
in vivoで造血幹細胞及び造血前駆細胞を形質導入するための方法及び組成物
|
WO2022197776A1
(en)
|
2021-03-16 |
2022-09-22 |
Magenta Therapeutics, Inc. |
Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
|